RE: No deal for me25 Apr 2018 12:19
From same ft article...
People involved in the talks said Mr Weber would probably face no major difficulty in securing loans from Japan’s three big banks, which had increasingly relied on acquisition-financing to earn fees in the country’s ultra-loose monetary environment.
The acquisition would add Shire's lucrative rare diseases portfolio to Takeda's pipeline, which lacked major late-development experimental drugs and was grappling with patent expiries on its blockbuster drugs.